GlaxoSmithKline plc and Genmab A/S have submitted a variation to the marketing authorisation application (MAA) to the European Medicines Agency (EMA) for the use of Arzerra (ofatumumab) in combination with an alkylator-based therapy, to be used for treatment of Chronic Lymphocytic Leukaemia (CLL) patients who have not received prior treatment and are inappropriate for fludarabine-based therapy (my emphasis- Neil).
The submission is based primarily on results from an international, multi-centre, randomised phase III study of ofatumumab in combination with chlorambucil versus chlorambucil alone in more than 400 patients with previously untreated CLL.
GSK and Genmab Announce Submission to US Regulatory Authorities for Arzerra(R) (Ofatumumab) as 1st Line Treatment of Chronic Lymphocytic Leukemia (CLL)
Patent is coming off rituxan... GSK is eyeing the 7 billion dollar a year market... ofatumumab has always been second fiddle, now rituxan may have some competition.
Watch for announcements of rituxan Biosimilars as well, many companies are waiting in the wings... for a slice of the pie... Sandoz and AstraZeneca appear to be on track as well as the Indian drug companies, Natco and Dr Reddys already have rituxan bios, Teva and Samsung have fallen by the wayside...
It will be interesting to see the role of Roche's new obinutuzumab ...
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.
